Picture supply: Getty Pictures
With the New 12 months upon us, I’ve been drawing up concepts for shares to purchase for my portfolio. Right here’s one among them.
Trying to find huge potential AI winners
The investing theme of 2024 was undoubtedly synthetic intelligence (AI). This revolutionary know-how has captured the general public’s creativeness in methods not seen because the delivery of the web.
Nvidia has been the standout winner to date, with its fill up 742% following the discharge of ChatGPT in November 2022. Shares of AI software program agency Palantir Applied sciences have executed even higher — up practically 1,000% over the identical interval!
Nonetheless, there are more likely to be extra huge AI winners because the know-how improves and is utilized to different areas. Tempus AI (NASDAQ: TEM) may simply be a kind of.
Utilizing AI to remodel most cancers care
Google-backed Tempus owns the world’s largest library of scientific and genomic knowledge, together with over 6m affected person information. It specialises in utilizing AI and knowledge analytics to advance precision drugs, significantly in oncology, by making sense of those huge unstructured datasets.
Physicians and researchers can use its AI-driven insights to personalise affected person care and pace up drug growth. The agency’s mission is “to assist ensure that sufferers are on the appropriate drug on the proper time“.
Scottish Mortgage Funding Belief is extremely bullish on the corporate. Its portfolio director not too long ago wrote: “Tempus sits on the intersection of two thrilling tendencies — genomic profiling and synthetic intelligence-driven well being knowledge…Trying ahead, we keep a excessive conviction in its capacity to supply excessive long-term returns, by utilizing AI to remodel most cancers care.”
Monetary efficiency
The agency is rising strongly. In Q3, income elevated by 33% yr on yr to $181m. For the complete yr, administration expects roughly $700m in income, which might characterize 32% development.
Founder and CEO Eric Lefkofsky commented: “The general enterprise carried out properly within the quarter, as demonstrated by accelerating quantity development in our genomics enterprise and accelerating income development in our knowledge and providers enterprise.”
Nonetheless, Tempus shouldn’t be but worthwhile, and recorded a internet loss of $75.8m in Q3. Investing in a loss-making enterprise would definitely add danger for me.
Additionally, the agency introduced the acquisition of Ambry Genetics, a frontrunner in genetic testing. This was for $375m in money ($300m of this financed by way of debt) and $225m in shares. It expects Ambry to generate over $300m in income and generate greater than $40m in EBITDA for 2024.
Debt provides additional danger, regardless that Tempus ought to nonetheless have round $350m in money following this acquisition.
The following superb revolution
Trying forward, analysts reckon the worldwide market measurement of AI in oncology might develop from $891m in 2022 to $10.7bn in 2032. Tempus is a frontrunner on this space, working with over 200 healthcare corporations, together with AstraZeneca and GSK.
In early 2024, Nvidia CEO Jensen Huang mentioned: “The place do I feel the subsequent superb revolution goes to return? There’s no query that digital biology goes to be it.”
Digital biology is the fusion of AI, huge knowledge, and healthcare. Due to this fact, Tempus appears to be like well-positioned for robust long-term development.
The share worth has crashed 50% since Donald Trump nominated Robert F Kennedy Jr to grow to be well being secretary. That appears like a large overreaction to me, and I’m contemplating profiting from the dip.